Skip to main content
. Author manuscript; available in PMC: 2023 Mar 15.
Published in final edited form as: Lancet HIV. 2022 Oct 26;9(12):e868–e883. doi: 10.1016/S2352-3018(22)00249-1

Figure: Timeline of two-drug antiretroviral therapy studies and guidelines.

Figure:

Two-drug regimens evaluated in each study: ATLAS-M: ritonavir-boosted atazanavir plus lamivudine;30,31 GARDEL: ritonavir-boosted lopinavir plus lamivudine;18 NEAT 001/ANRS 143: ritonavir-boosted darunavir plus raltegravir;19 SALT: ritonavir-boosted atazanavir plus lamivudine;28,29 OLE: ritonavir-boosted lopinavir plus lamivudine;27 LATTE-2: long-acting cabotegravir plus long-acting rilpivirine;53 DUAL-GESIDA 8014-RIS-EST45: ritonavir-boosted darunavir plus lamivudine;32 SWORD 1 and 2: dolutegravir plus rilpivirine;24–26 GEMINI 1 and 2: dolutegravir plus lamivudine;16,17 ATLAS: long-acting cabotegravir plus long-acting rilpivirine;38 FLAIR: long-acting cabotegravir plus long-acting rilpivirine;35,37 PROBE-2: cobicistat-boosted darunavir plus rilpivirine;34 DUALIS: dolutegravir plus ritonavir-boosted darunavir;33 TANGO: dolutegravir plus lamivudine;20,21 SALSA: dolutegravir plus lamivudine;23 DOLAM: dolutegravir plus lamivudine;22 ATLAS-2M: long-acting cabotegravir plus long-acting rilpivirine.39–41 3TC=lamivudine. bATV=boosted atazanavir. bDRV=boosted darunavir. bLPV=boosted lopinavir. bPI=boosted protease inhibitor. CAB=cabotegravir. DHHS=Department of Health and Human Services. DTG=dolutegravir. EACS=European AIDS Clinical Society. FTC=emtricitabine. IAS=International Antiviral Society. RAL=raltegravir. RPV=rilpivirine.